ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
05. November 2024 09:00 ET
|
ImCheck Therapeutics SAS
ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer Marseille, France, November 5, 2024, 3 pm CET – ImCheck Therapeutics...
ImCheck Appoints Stephan Braun as Chief Medical Officer
09. Juli 2024 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck Appoints Stephan Braun as Chief Medical Officer Marseille, France, July 09, 2024 – ImCheck Therapeutics announced today the appointment of Stephan Braun, M.D., Ph.D., as Chief...
Correction: ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
18. Oktober 2023 15:50 ET
|
ImCheck Therapeutics SAS
ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety...
ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
15. Oktober 2023 18:05 ET
|
ImCheck Therapeutics SAS
ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety...
ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
03. Februar 2022 05:03 ET
|
ImCheck Therapeutics SAS
ImCheck Announces First Patients Dosedin Phase II of EVICTION Trial for ICT01 EVICTION trial proceeds to Phase IIa based on promising Phase I patient datafor ICT01 across a broad range of...
ImCheck Therapeutics Appoints Dr. Loui Madakamutil as CSO
15. April 2021 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck Therapeutics Appoints Dr. Loui Madakamutil, Noted Expert in Immunology and Autoimmune Diseases, as Chief Scientific Officer Marseille, France, April 15, 2021 – ImCheck Therapeutics today...
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021
11. März 2021 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting...
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01
10. September 2020 05:46 ET
|
ImCheck Therapeutics SAS
ImCheck Achieves Initial Positive Independent Safety Reviewand Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01 Company Receives FDA Approval for US IND ...
ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer
09. Juli 2020 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer First hire in the US will support growing global business development activities Marseille, France, July 9, 2020 – ImCheck...